GERON CORP (GERN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -51.77M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | 154.96M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-51.77M | (m) | (m) | (m) | $154.96M | (m) |
| 2026-03-31 | $-51.72M | (m) | (m) | (m) | $154.66M | (m) |
| 2025-12-31 | $-68.58M | (m) | (m) | (m) | $159.26M | (m) |
| 2025-09-30 | $-63.09M | (m) | (m) | (m) | $160.96M | (m) |
| 2025-06-30 | $-77.42M | (m) | (m) | (m) | $157.84M | (m) |
| 2025-03-31 | $-134.30M | (m) | (m) | (m) | $158.69M | (m) |
| 2024-12-31 | $-173.73M | (m) | (m) | (m) | $145.73M | (m) |
| 2024-09-30 | $-207.97M | $29.48M | (m) | (m) | (m) | -705.46% |
| 2024-06-30 | $-227.37M | $1.37M | (m) | (m) | (m) | -16559.94% |
| 2024-03-31 | $-209.99M | $520.00K | (m) | (m) | (m) | -40381.92% |
| 2023-12-31 | $-193.94M | $237.00K | (m) | (m) | (m) | -81832.91% |
| 2023-09-30 | $-181.61M | $317.00K | (m) | (m) | (m) | -57288.96% |
| 2023-06-30 | $-173.94M | $450.00K | (m) | (m) | (m) | -38653.78% |
| 2023-03-31 | $-149.97M | $494.00K | (m) | (m) | (m) | -30357.69% |
| 2022-12-31 | $-138.55M | $596.00K | (m) | (m) | (m) | -23246.64% |
| 2022-09-30 | $-127.58M | $1.53M | (m) | (m) | (m) | -8322.31% |
| 2022-06-30 | $-113.31M | $1.34M | (m) | (m) | (m) | -8424.31% |
| 2022-03-31 | $-114.22M | $1.38M | (m) | (m) | (m) | -8282.81% |
| 2021-12-31 | $-114.00M | $1.39M | (m) | (m) | (m) | -8183.70% |
| 2021-09-30 | $-106.28M | $403.00K | (m) | (m) | (m) | -26372.95% |
| 2021-06-30 | $-100.62M | $402.00K | (m) | (m) | (m) | -25030.85% |
| 2021-03-31 | $-88.50M | $338.00K | (m) | (m) | (m) | -26182.54% |
| 2020-12-31 | $-76.91M | $253.00K | (m) | (m) | (m) | -30400.40% |
| 2020-09-30 | $-83.66M | $374.00K | (m) | (m) | (m) | -22367.65% |
| 2020-06-30 | $-79.61M | $397.00K | (m) | (m) | (m) | -20053.40% |
| 2020-03-31 | $-78.07M | $455.00K | (m) | (m) | (m) | -17159.12% |
| 2019-12-31 | $-72.50M | $460.00K | (m) | (m) | (m) | -15761.96% |
| 2019-09-30 | $-52.09M | $664.00K | (m) | (m) | (m) | -7844.28% |
| 2019-06-30 | $-42.92M | $698.00K | (m) | (m) | (m) | -6148.85% |
| 2019-03-31 | $-34.94M | $805.00K | (m) | (m) | (m) | -4340.00% |
| 2018-12-31 | $-31.07M | $1.07M | (m) | (m) | (m) | -2914.92% |
| 2018-09-30 | $-29.27M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-29.71M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-29.20M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-29.25M | $1.06M | (m) | (m) | (m) | -2746.95% |
| 2017-09-30 | $-30.25M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-26.88M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-29.06M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-30.65M | $6.16M | (m) | (m) | (m) | -497.34% |
| 2016-09-30 | $-30.51M | $6.29M | (m) | (m) | (m) | -485.19% |
| 2016-06-30 | $388.00K | $36.54M | (m) | (m) | (m) | 1.06% |
| 2016-03-31 | $-180.00K | $36.58M | (m) | (m) | (m) | -0.49% |
| 2015-12-31 | $-559.00K | $36.37M | (m) | (m) | (m) | -1.54% |
| 2015-09-30 | $-926.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-37.85M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-37.04M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-36.31M | $1.15M | (m) | (m) | (m) | -3149.35% |
| 2014-09-30 | $-36.58M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-35.40M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-35.70M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-38.96M | $1.28M | (m) | (m) | (m) | -3036.48% |
| 2013-09-30 | $-48.17M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-55.31M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-64.83M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-71.76M | $2.71M | (m) | (m) | (m) | -2648.87% |
| 2012-09-30 | $-83.68M | $2.27M | (m) | (m) | (m) | -3684.81% |
| 2012-06-30 | $-87.74M | $1.85M | (m) | (m) | (m) | -4729.97% |
| 2012-03-31 | $-90.68M | $2.19M | (m) | (m) | (m) | -4146.23% |
| 2011-12-31 | $-96.12M | $2.44M | (m) | (m) | (m) | -3942.41% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-111.17M | $3.56M | (m) | (m) | (m) | -3120.04% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-70.23M | $1.73M | (m) | (m) | (m) | -4069.18% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |